The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Erythropoietin Stimulating Agents-Global Market Insights and Sales Trends 2024
Synopsis
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS.
The global Erythropoietin Stimulating Agents market size is expected to reach US$ 12520 million by 2029, growing at a CAGR of 4.2% from 2023 to 2029. The market is mainly driven by the significant applications of Erythropoietin Stimulating Agents in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Erythropoietin Stimulating Agents market. Epoetin Alfa, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Epoetin Beta segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Erythropoietin Stimulating Agents market, driven by demand from China, the second largest economy with some signs of stabilising, the Erythropoietin Stimulating Agents market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Erythropoietin Stimulating Agents, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Erythropoietin Stimulating Agents market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Erythropoietin Stimulating Agents market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Erythropoietin Stimulating Agents sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Erythropoietin Stimulating Agents covered in this report include Pfizer, Amgen, BioSidus, Biocon, Celltrion, Roche, Intas Pharmaceuticals, Johnson & Johnson and Teva Pharmaceutical Industries, etc.
The global Erythropoietin Stimulating Agents market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Amgen
BioSidus
Biocon
Celltrion
Roche
Intas Pharmaceuticals
Johnson & Johnson
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Global Erythropoietin Stimulating Agents market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Erythropoietin Stimulating Agents market, Segment by Type:
Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Others
Global Erythropoietin Stimulating Agents market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Erythropoietin Stimulating Agents companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS.
The global Erythropoietin Stimulating Agents market size is expected to reach US$ 12520 million by 2029, growing at a CAGR of 4.2% from 2023 to 2029. The market is mainly driven by the significant applications of Erythropoietin Stimulating Agents in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Erythropoietin Stimulating Agents market. Epoetin Alfa, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Epoetin Beta segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Erythropoietin Stimulating Agents market, driven by demand from China, the second largest economy with some signs of stabilising, the Erythropoietin Stimulating Agents market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Erythropoietin Stimulating Agents, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Erythropoietin Stimulating Agents market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Erythropoietin Stimulating Agents market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Erythropoietin Stimulating Agents sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Erythropoietin Stimulating Agents covered in this report include Pfizer, Amgen, BioSidus, Biocon, Celltrion, Roche, Intas Pharmaceuticals, Johnson & Johnson and Teva Pharmaceutical Industries, etc.
The global Erythropoietin Stimulating Agents market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Amgen
BioSidus
Biocon
Celltrion
Roche
Intas Pharmaceuticals
Johnson & Johnson
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Global Erythropoietin Stimulating Agents market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Erythropoietin Stimulating Agents market, Segment by Type:
Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Others
Global Erythropoietin Stimulating Agents market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Erythropoietin Stimulating Agents companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Erythropoietin Stimulating Agents
1.1 Erythropoietin Stimulating Agents Market Overview
1.1.1 Erythropoietin Stimulating Agents Product Scope
1.1.2 Erythropoietin Stimulating Agents Market Status and Outlook
1.2 Global Erythropoietin Stimulating Agents Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Erythropoietin Stimulating Agents Market Size by Region (2018-2029)
1.4 Global Erythropoietin Stimulating Agents Historic Market Size by Region (2018-2023)
1.5 Global Erythropoietin Stimulating Agents Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Erythropoietin Stimulating Agents Market Size (2018-2029)
1.6.1 North America Erythropoietin Stimulating Agents Market Size (2018-2029)
1.6.2 Europe Erythropoietin Stimulating Agents Market Size (2018-2029)
1.6.3 Asia-Pacific Erythropoietin Stimulating Agents Market Size (2018-2029)
1.6.4 Latin America Erythropoietin Stimulating Agents Market Size (2018-2029)
1.6.5 Middle East & Africa Erythropoietin Stimulating Agents Market Size (2018-2029)
2 Erythropoietin Stimulating Agents Market by Type
2.1 Introduction
2.1.1 Epoetin Alfa
2.1.2 Epoetin Beta
2.1.3 Darbepoetin Alfa
2.1.4 Others
2.2 Global Erythropoietin Stimulating Agents Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Erythropoietin Stimulating Agents Historic Market Size by Type (2018-2023)
2.2.2 Global Erythropoietin Stimulating Agents Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Erythropoietin Stimulating Agents Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Erythropoietin Stimulating Agents Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Erythropoietin Stimulating Agents Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Erythropoietin Stimulating Agents Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Erythropoietin Stimulating Agents Revenue Breakdown by Type (2018-2029)
3 Erythropoietin Stimulating Agents Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Erythropoietin Stimulating Agents Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Erythropoietin Stimulating Agents Historic Market Size by Application (2018-2023)
3.2.2 Global Erythropoietin Stimulating Agents Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Erythropoietin Stimulating Agents Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Erythropoietin Stimulating Agents Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Erythropoietin Stimulating Agents Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Erythropoietin Stimulating Agents Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Erythropoietin Stimulating Agents Revenue Breakdown by Application (2018-2029)
4 Erythropoietin Stimulating Agents Competition Analysis by Players
4.1 Global Erythropoietin Stimulating Agents Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Erythropoietin Stimulating Agents as of 2022)
4.3 Date of Key Players Enter into Erythropoietin Stimulating Agents Market
4.4 Global Top Players Erythropoietin Stimulating Agents Headquarters and Area Served
4.5 Key Players Erythropoietin Stimulating Agents Product Solution and Service
4.6 Competitive Status
4.6.1 Erythropoietin Stimulating Agents Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Erythropoietin Stimulating Agents Products, Services and Solutions
5.1.4 Pfizer Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Erythropoietin Stimulating Agents Products, Services and Solutions
5.2.4 Amgen Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 BioSidus
5.3.1 BioSidus Profile
5.3.2 BioSidus Main Business
5.3.3 BioSidus Erythropoietin Stimulating Agents Products, Services and Solutions
5.3.4 BioSidus Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.3.5 Biocon Recent Developments
5.4 Biocon
5.4.1 Biocon Profile
5.4.2 Biocon Main Business
5.4.3 Biocon Erythropoietin Stimulating Agents Products, Services and Solutions
5.4.4 Biocon Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.4.5 Biocon Recent Developments
5.5 Celltrion
5.5.1 Celltrion Profile
5.5.2 Celltrion Main Business
5.5.3 Celltrion Erythropoietin Stimulating Agents Products, Services and Solutions
5.5.4 Celltrion Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.5.5 Celltrion Recent Developments
5.6 Roche
5.6.1 Roche Profile
5.6.2 Roche Main Business
5.6.3 Roche Erythropoietin Stimulating Agents Products, Services and Solutions
5.6.4 Roche Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.6.5 Roche Recent Developments
5.7 Intas Pharmaceuticals
5.7.1 Intas Pharmaceuticals Profile
5.7.2 Intas Pharmaceuticals Main Business
5.7.3 Intas Pharmaceuticals Erythropoietin Stimulating Agents Products, Services and Solutions
5.7.4 Intas Pharmaceuticals Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.7.5 Intas Pharmaceuticals Recent Developments
5.8 Johnson & Johnson
5.8.1 Johnson & Johnson Profile
5.8.2 Johnson & Johnson Main Business
5.8.3 Johnson & Johnson Erythropoietin Stimulating Agents Products, Services and Solutions
5.8.4 Johnson & Johnson Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.8.5 Johnson & Johnson Recent Developments
5.9 Teva Pharmaceutical Industries
5.9.1 Teva Pharmaceutical Industries Profile
5.9.2 Teva Pharmaceutical Industries Main Business
5.9.3 Teva Pharmaceutical Industries Erythropoietin Stimulating Agents Products, Services and Solutions
5.9.4 Teva Pharmaceutical Industries Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.9.5 Teva Pharmaceutical Industries Recent Developments
5.10 Thermo Fisher Scientific
5.10.1 Thermo Fisher Scientific Profile
5.10.2 Thermo Fisher Scientific Main Business
5.10.3 Thermo Fisher Scientific Erythropoietin Stimulating Agents Products, Services and Solutions
5.10.4 Thermo Fisher Scientific Erythropoietin Stimulating Agents Revenue (US$ Million) & (2018-2023)
5.10.5 Thermo Fisher Scientific Recent Developments
6 North America
6.1 North America Erythropoietin Stimulating Agents Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Erythropoietin Stimulating Agents Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Erythropoietin Stimulating Agents Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Erythropoietin Stimulating Agents Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Erythropoietin Stimulating Agents Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Erythropoietin Stimulating Agents Market Dynamics
11.1 Erythropoietin Stimulating Agents Industry Trends
11.2 Erythropoietin Stimulating Agents Market Drivers
11.3 Erythropoietin Stimulating Agents Market Challenges
11.4 Erythropoietin Stimulating Agents Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
